# Glycocoumarin (Glycine tabacina-derived coumarin glycoside)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/glycocoumarin-glycine-tabacina-derived-coumarin-glycoside
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-03
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** Dolichosin A, Coumarin glycoside, Glycosylated coumarin, Glycine tabacina bioactive, Coumarin-O-glucoside

## Overview

Glycocoumarin, exemplified by the compound dolichosin A isolated from Glycine tabacina, exerts anti-inflammatory and antiproliferative effects primarily through inhibition of the PI3K/AKT and MAPK signaling cascades, suppressing fibroblast-like synoviocyte proliferation and [pro-inflammatory cytokine](/ingredients/condition/inflammation) production. In preclinical models, structurally related glycosylated coumarins have demonstrated tumor growth inhibition at 30 mg/kg in murine mammary tumor models and carbonic anhydrase IX/XII inhibition in the low nanomolar range, though no human clinical trial data currently exists to confirm these effects.

## Health Benefits

- **[Anti-Inflammatory](/ingredients/condition/inflammation) Activity**: Dolichosin A suppresses the production of IL-1β, IL-6, and TNF-α in synoviocytes and macrophage cell lines by inhibiting PI3K/AKT and MAPK pathways, reducing inflammatory gene expression relevant to rheumatoid arthritis and other chronic inflammatory conditions.
- **Anti-HIV / [Antiviral](/ingredients/condition/immune-support) Potential**: Glycocoumarin has been identified as an inhibitor of HIV-induced syncytia (giant cell) formation in vitro, blocking viral cytopathic effects without producing observable cytotoxicity in host cells, suggesting a selective antiviral mechanism.
- **Antitumor and Antiangiogenic Effects**: Coumarin glycosides inhibit tumor-associated carbonic anhydrase isoforms CA IX and CA XII in the low nanomolar range, disrupting pH homeostasis in hypoxic tumor microenvironments and attenuating tumor growth, as demonstrated in 4T1 murine mammary tumor models at 30 mg/kg.
- **Fibroblast-Like Synoviocyte (FLS) Proliferation Inhibition**: Network pharmacology and in vitro data indicate dolichosin A reduces aberrant FLS proliferation, a hallmark of rheumatoid arthritis joint destruction, through multimodal pathway suppression rather than a single target interaction.
- **COX-2 and Nitric Oxide Synthase Downregulation**: Glycocoumarin compounds modulate cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW264.7 macrophage models, reducing prostaglandin E2 and nitric oxide levels that drive acute and chronic inflammatory responses.
- **[Neuroprotective](/ingredients/condition/cognitive) Potential**: Broader coumarin glycosides exhibit monoamine oxidase (MAO) inhibitory activity and glutamate regulation in hippocampal tissue models, suggesting relevance to neurodegenerative and mood-related conditions, though this is not yet directly demonstrated for glycocoumarin specifically.
- **Mucosal Cytoprotection**: General coumarin-class compounds have shown preliminary evidence of mucosal protective effects in radiotherapy patients with head and neck cancers, with glycosylation potentially enhancing tissue targeting and solubility relevant to this activity.

## Mechanism of Action

Dolichosin A, the primary characterized glycocoumarin from Glycine tabacina, inhibits the PI3K/AKT signaling axis and downstream MAPK cascade (including ERK1/2 and p38 phosphorylation), thereby blocking transcription factors such as NF-κB that regulate [pro-inflammatory cytokine](/ingredients/condition/inflammation) gene expression including IL-1β, IL-6, and TNF-α. At the enzymatic level, coumarin glycosides competitively inhibit tumor-associated carbonic anhydrase isoforms IX and XII with Ki values in the low nanomolar range, disrupting intracellular and extracellular pH buffering that hypoxic tumor cells depend upon for survival and proliferation. The glycosyl moiety attached to the coumarin scaffold enhances aqueous solubility and may facilitate receptor-mediated cellular uptake through sugar transporter systems, improving bioavailability at target tissues compared to aglycone coumarins. Additionally, glycocoumarin downregulates COX-2 and inducible nitric oxide synthase at the transcriptional level in macrophage models, and its anti-HIV activity is attributed to interference with viral envelope-mediated cell fusion processes that generate multinucleated syncytia, a cytopathic mechanism central to HIV-1 pathogenesis.

## Clinical Summary

No clinical trials have been conducted specifically on glycocoumarin or its primary characterized compound dolichosin A in human subjects. Preclinical outcomes include inhibition of fibroblast-like synoviocyte proliferation in rheumatoid arthritis cell models, tumor growth reduction in murine mammary tumor models at 30 mg/kg, and anti-HIV syncytia inhibition in vitro without measurable cytotoxicity. These findings provide mechanistic rationale for further development but do not establish efficacious doses, pharmacokinetic parameters, or safety thresholds in humans. Confidence in translational relevance is low until Phase I and Phase II human studies define bioavailability, tolerability, and dose-response relationships.

## Nutritional Profile

Glycocoumarin is a specialized secondary metabolite and not a macronutrient or micronutrient source; it contributes no meaningful caloric, protein, fat, or carbohydrate content in physiological quantities. As a coumarin glycoside, its molecular structure consists of a benzopyranone (coumarin) core linked to one or more sugar residues (typically glucose or rhamnose), conferring enhanced water solubility compared to free aglycone coumarins. The glycosyl moiety improves intestinal absorption through active sugar transporter-mediated uptake, though overall oral bioavailability remains poorly quantified and is expected to be limited based on general coumarin pharmacokinetics. Dolichosin A and related glycocoumarins are present in trace concentrations in plant material, with no quantified standardized concentration data available in published literature; phytochemical co-occurrence with isoflavones, flavonoids, and other phenolic compounds in Glycine tabacina may contribute to observed synergistic biological activities.

## Dosage & Preparation

- **Research Extract (Preclinical)**: 30 mg/kg body weight administered in murine in vivo tumor models; no human-equivalent dose established or validated
- **Phytochemical Isolation**: Typically extracted from Glycine tabacina aerial parts via maceration in methanol or ethanol, or microwave-assisted extraction, followed by chromatographic purification (silica gel, HPLC); not commercially available as a standardized supplement
- **Traditional Botanical Preparation**: Plants containing coumarin glycosides are prepared as water decoctions or alcohol tinctures in TCM practice, though glycocoumarin is not individually standardized in these formulations
- **Standardization**: No pharmacopeial standardization or certificate-of-analysis benchmarks exist for glycocoumarin content in any commercial product
- **Timing and Administration**: No clinical data exists to support specific timing recommendations; preclinical dosing was systemic (intraperitoneal or oral gavage in rodents)
- **Note**: Glycocoumarin is not currently available as a standalone dietary supplement; any exposure occurs incidentally through consumption of glycocoumarin-containing botanical preparations

## Safety & Drug Interactions

No formal toxicological or safety studies have been published specifically for glycocoumarin or dolichosin A, making it impossible to define a maximum safe dose, NOAEL, or established adverse effect profile for this compound in humans. As a member of the coumarin class, glycocoumarin carries theoretical risk of potentiating anticoagulant effects when combined with warfarin, heparin, or antiplatelet agents such as aspirin and clopidogrel, due to the vitamin K antagonism and platelet aggregation inhibition associated with coumarin-class compounds, though this has not been directly demonstrated for glycocoumarin specifically. Ulcerogenic potential and hepatotoxicity have been reported with high-dose coumarin exposure in general, suggesting that caution is warranted in individuals with hepatic impairment, peptic ulcer disease, or coagulation disorders. Glycocoumarin should not be used during pregnancy or lactation due to the complete absence of safety data, and the general teratogenic and anticoagulant risks associated with coumarin-class compounds mandate avoidance until controlled safety studies are conducted.

## Scientific Research

Research on glycocoumarin is confined entirely to preclinical stages, with no published human clinical trials as of current literature; evidence derives from in vitro cell culture experiments (RAW264.7 macrophages, human FLS cells), network pharmacology computational screening, and in vivo rodent models such as carrageenan-induced paw edema and 4T1 murine mammary tumor xenografts. The murine tumor model using 30 mg/kg dosing demonstrated measurable tumor growth inhibition, but study parameters including sample size, duration, and comparative controls are incompletely reported in available secondary sources. For coumarins broadly, one study examined mucosal protection in head and neck radiotherapy patients, but specific sample sizes, effect sizes, and statistical confidence levels were not reported with sufficient detail to evaluate. The overall evidence base for glycocoumarin as a distinct therapeutic entity is nascent and preliminary, with network pharmacology analyses identifying molecular targets computationally but requiring rigorous validation through controlled in vivo dose-response studies and eventual Phase I human pharmacokinetic trials.

## Historical & Cultural Context

Glycine tabacina, the primary plant source of dolichosin A, has a history of use in traditional Chinese medicine as part of broader herbal formulas targeting joint inflammation, rheumatic pain, and immune dysregulation, though the plant was not historically used with knowledge of its specific coumarin glycoside constituents. The broader class of coumarin-containing plants has deep ethnobotanical roots across Asian, European, and South American traditional medicine systems, where they were employed for anticoagulant, [anti-inflammatory](/ingredients/condition/inflammation), and wound-healing properties, with sweet clover (Melilotus officinalis) being one of the most historically significant coumarin sources. Coumarin glycosides as isolated chemical entities represent a modern phytochemical refinement of this traditional knowledge, with systematic isolation beginning in the 20th century as analytical chemistry enabled identification of individual bioactive constituents within complex botanical extracts. The anti-HIV investigation of glycocoumarin emerged from ethnopharmacological screening programs in the 1990s and early 2000s that systematically evaluated tropical and subtropical legumes for [antiviral](/ingredients/condition/immune-support) activity, placing Glycine tabacina within a broader research paradigm linking traditional plant use to novel antiviral drug discovery.

## Synergistic Combinations

Glycocoumarin's PI3K/AKT and MAPK inhibitory activity may be synergistically enhanced when combined with other natural NF-κB pathway suppressors such as curcumin or resveratrol, as these compounds act at complementary nodes within the inflammatory signaling network, potentially allowing dose reduction of each agent. The glycosylation-enhanced solubility of glycocoumarin may be further leveraged through co-formulation with phospholipid complexes (phytosomes) or cyclodextrins, which are known to improve the oral bioavailability of phenolic natural compounds and could address the poor absorption that limits coumarin-class bioactivity. In the context of rheumatoid arthritis, pairing dolichosin A-containing botanical extracts with omega-3 fatty acids (EPA/DHA) represents a mechanistically rational combination, as omega-3s suppress leukotriene and prostaglandin synthesis through COX/LOX inhibition while glycocoumarin targets upstream kinase signaling, providing complementary multi-pathway [anti-inflammatory](/ingredients/condition/inflammation) coverage.

## Frequently Asked Questions

### What is glycocoumarin and where does it come from?

Glycocoumarin is a class of glycosylated coumarin compounds in which a sugar moiety is attached to the benzopyranone coumarin scaffold, enhancing solubility and bioactivity. The best-characterized member, dolichosin A, is isolated from Glycine tabacina, a leguminous plant native to East and Southeast Asia, and has been identified through phytochemical analysis and network pharmacology as a key bioactive with anti-inflammatory and antiviral potential.

### How does glycocoumarin work against HIV?

Glycocoumarin inhibits the formation of HIV-induced syncytia — multinucleated giant cells produced when viral envelope glycoproteins fuse infected and uninfected CD4+ T cells — which is a major cytopathic mechanism of HIV-1 pathogenesis. Critically, this inhibition occurs without measurable cytotoxicity to host cells in vitro, suggesting a selective mechanism that targets viral fusion processes rather than broadly damaging cellular function, though the precise molecular target mediating this anti-HIV activity has not yet been fully characterized.

### Is glycocoumarin safe to take as a supplement?

Glycocoumarin is not currently available as a commercial dietary supplement, and no formal human safety or toxicology studies have been published for this compound. As a coumarin-class molecule, it carries theoretical risks of anticoagulant effects and potential hepatotoxicity at high doses, and it should not be combined with warfarin or antiplatelet drugs without medical supervision. Anyone considering botanical preparations containing Glycine tabacina should consult a healthcare provider, and use during pregnancy or lactation is not recommended due to the complete absence of safety data.

### What is the evidence for glycocoumarin in rheumatoid arthritis?

Current evidence for glycocoumarin in rheumatoid arthritis is limited to preclinical studies, including in vitro experiments in human fibroblast-like synoviocytes and RAW264.7 macrophages, as well as carrageenan-induced paw edema models in rodents. Dolichosin A has been shown computationally and experimentally to inhibit PI3K/AKT and MAPK pathways, reducing IL-1β, IL-6, and TNF-α production, but no human clinical trials have been conducted, meaning these findings cannot yet be translated into therapeutic recommendations.

### What dose of glycocoumarin has been studied?

The only published in vivo dosing data for glycocoumarin-class compounds involves 30 mg/kg body weight administered to mice in mammary tumor models, which demonstrated measurable tumor growth inhibition. No human pharmacokinetic studies exist to establish a human-equivalent dose, oral bioavailability, or safe dosing range, and no standardized supplement form is commercially available, making any extrapolation of these rodent doses to human supplementation premature and potentially misleading.

### Does glycocoumarin interact with antiretroviral medications used to treat HIV?

While glycocoumarin has demonstrated HIV-inhibitory activity in laboratory studies, there is limited clinical data on interactions with antiretroviral drugs such as protease inhibitors or integrase inhibitors. Anyone taking HIV medications should consult their healthcare provider before adding glycocoumarin supplements, as coumarins can potentially affect drug metabolism through cytochrome P450 pathways. Current evidence is insufficient to recommend glycocoumarin as a complementary therapy alongside standard antiretroviral treatment.

### Is glycocoumarin safe to take with immunosuppressant medications used for rheumatoid arthritis?

Glycocoumarin's anti-inflammatory mechanism via PI3K/AKT and MAPK inhibition could potentially enhance or interfere with immunosuppressant drugs like TNF-α inhibitors or methotrexate. No clinical trials have directly evaluated co-administration of glycocoumarin with these medications, making safety assessment difficult. Patients using immunosuppressant therapy should obtain medical guidance before supplementing with glycocoumarin to avoid unintended immunological effects.

### What is the difference between glycocoumarin and other coumarin compounds found in supplements?

Glycocoumarin is a coumarin glycoside specifically derived from Glycine tabacina and structurally differs from simple coumarins like those in warfarin or dietary coumarins in cinnamon by its attached sugar moiety, which may affect absorption and bioavailability. This glycoside structure is thought to enhance its anti-inflammatory and antiviral properties compared to non-glycosylated coumarins. Unlike some coumarin sources, glycocoumarin's isolated form in research has shown targeted activity against specific inflammatory pathways relevant to rheumatoid arthritis.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*